Literature DB >> 10712664

Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis.

K H Sun1, C L Yu, S J Tang, G H Sun.   

Abstract

In our previous reports, we found polyclonal anti-double-stranded DNA antibodies (anti-dsDNA) purified from patients with active systemic lupus erythematosus (SLE) exerted inhibitory effect on [3H]thymidine incorporation of human mononuclear cells (MNC). However, the other immunological effects of anti-dsDNA on the functions of MNC have not yet been reported. In this study, two monoclonal antibodies, 12B3 and 9D7, with different anti-dsDNA activity were evaluated for their effects on the expression and release of different cytokines from human MNC. We confirmed absence of endotoxin in the two monoclonal antibody preparations and the used medium as detected by Limulus amoebocyte lysate test. The mRNA expression and release of different cytokines including interleukin (IL)-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) were measured. We found the two monoclonal anti-dsDNA not only dose-responsively suppressed the phytohaemagglutinin (PHA)-induced thymidine uptake of human MNC but stimulated the mRNA expression of IL-1beta, IL-6 and IL-8 in normal human MNC detected by reverse transcription-polymerase chain reaction (RT-PCR). Enzyme-linked immunosorbent assay (ELISA) measurement of cytokines in MNC culture supernatants revealed that anti-dsDNA enhanced IL-1beta, IL-8, TNF-alpha and IL-10 release from resting MNC. These effects of anti-dsDNA antibodies were not affected by polymyxin B, a potent binder and neutralizer of lipopolysaccharide (LPS). These in vitro studies suggest that anti-dsDNA possess a dual effect on normal human MNC: (a) to enhance the release of proinflammatory cytokines (IL-1beta, IL-8 and TNF-alpha) from MNC to augment inflammatory reaction; and (b) to polarize the immune reaction towards the T helper 2 (Th2) (increased IL-10 production) pathway. This unique effect of anti-dsDNA may play a role in lupus pathogenesis by augmenting inflammatory reactions and autoantibody production which are commonly found in patients with active SLE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712664      PMCID: PMC2327177          DOI: 10.1046/j.1365-2567.2000.00970.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  40 in total

1.  Anti-dsDNA antibodies cross-react with ribosomal P proteins expressed on the surface of glomerular mesangial cells to exert a cytostatic effect.

Authors:  K H Sun; W T Liu; C Y Tsai; S J Tang; S H Han; C L Yu
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

2.  Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

Authors:  B K Finck; B Chan; D Wofsy
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

3.  Polyclonal IgG anti-dsDNA antibodies exert cytotoxic effect on cultured rat mesangial cells by binding to cell membrane and augmenting apoptosis.

Authors:  C Y Tsai; T H Wu; K H Sun; T S Liao; W M Lin; C L Yu
Journal:  Scand J Rheumatol       Date:  1993       Impact factor: 3.641

4.  High levels of TH2 cytokine gene expression in systemic lupus erythematosus.

Authors:  Y Richaud-Patin; J Alcocer-Varela; L Llorente
Journal:  Rev Invest Clin       Date:  1995 Jul-Aug       Impact factor: 1.451

5.  Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies.

Authors:  K N Lai; J C Leung; K B Lai; F M Lai; K C Wong
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

6.  Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein.

Authors:  Y Levy; J C Brouet
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

7.  Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders.

Authors:  R A Stuart; A J Littlewood; P J Maddison; N D Hall
Journal:  Clin Exp Rheumatol       Date:  1995 Jan-Feb       Impact factor: 4.473

8.  Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-1 and interferon-gamma mRNA in the lymph nodes of lupus-prone mice.

Authors:  G J Prud'homme; D H Kono; A N Theofilopoulos
Journal:  Mol Immunol       Date:  1995-05       Impact factor: 4.407

9.  Abnormal splenic and thymic IL-4 and TNF-alpha expression in MRL-lpr/lpr mice.

Authors:  C Y Tsai; T H Wu; S F Huang; K H Sun; S C Hsieh; S H Han; H S Yu; C L Yu
Journal:  Scand J Immunol       Date:  1995-02       Impact factor: 3.487

10.  Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.

Authors:  L Llorente; W Zou; Y Levy; Y Richaud-Patin; J Wijdenes; J Alcocer-Varela; B Morel-Fourrier; J C Brouet; D Alarcon-Segovia; P Galanaud; D Emilie
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  24 in total

1.  Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.

Authors:  Seyed Mostafa Monzavi; Aida Alirezaei; Zhaleh Shariati-Sarabi; Jalil Tavakol Afshari; Mahmoud Mahmoudi; Banafsheh Dormanesh; Faezeh Jahandoost; Ali Reza Khoshdel; Ali Etemad Rezaie
Journal:  Inflammopharmacology       Date:  2018-07-10       Impact factor: 4.473

Review 2.  Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances.

Authors:  Desmond Yat Hin Yap; Kar Neng Lai
Journal:  J Biomed Biotechnol       Date:  2010-05-06

Review 3.  Alarmins, inflammasomes and immunity.

Authors:  Najwane Saïd-Sadier; David M Ojcius
Journal:  Biomed J       Date:  2012 Nov-Dec       Impact factor: 4.910

Review 4.  Rationale for interleukin-6 blockade in systemic lupus erythematosus.

Authors:  E Tackey; P E Lipsky; G G Illei
Journal:  Lupus       Date:  2004       Impact factor: 2.911

5.  Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjögren's syndrome features in lupus-prone Sle1.Yaa mice.

Authors:  Jacen S Maier-Moore; Christopher G Horton; Shirley A Mathews; Anthony W Confer; Christina Lawrence; Zijian Pan; K Mark Coggeshall; A Darise Farris
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

6.  Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease.

Authors:  Maida Wong; Antonio La Cava; Bevra H Hahn
Journal:  J Immunol       Date:  2013-05-01       Impact factor: 5.422

Review 7.  DNA-damaging autoantibodies and cancer: the lupus butterfly theory.

Authors:  Philip W Noble; Sasha Bernatsky; Ann E Clarke; David A Isenberg; Rosalind Ramsey-Goldman; James E Hansen
Journal:  Nat Rev Rheumatol       Date:  2016-03-24       Impact factor: 20.543

8.  Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses' Health Study cohorts.

Authors:  Medha Barbhaiya; Sara K Tedeschi; Bing Lu; Susan Malspeis; David Kreps; Jeffrey A Sparks; Elizabeth W Karlson; Karen H Costenbader
Journal:  Ann Rheum Dis       Date:  2017-10-07       Impact factor: 19.103

9.  Synergetic Interaction of HLA-DRB1*07 Allele and TNF-Alpha - 863 C/A Single Nucleotide Polymorphism in the Susceptibility to Systemic Lupus Erythematosus.

Authors:  Shiva Krishna Katkam; Liza Rajasekhar; Fathima S D Tasneem; Vijay Kumar Kutala
Journal:  Indian J Clin Biochem       Date:  2019-10-18

Review 10.  T Cell Homeostatic Proliferation Promotes a Redox State That Drives Metabolic and Epigenetic Upregulation of Inflammatory Pathways in Lupus.

Authors:  Ralph C Budd; Christopher D Scharer; Ramiro Barrantes-Reynolds; Scott Legunn; Karen A Fortner
Journal:  Antioxid Redox Signal       Date:  2021-11-09       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.